INTRODUCTION
============

Alopecia areata (AA) is an autoimmune disorder causing non-scarring hair loss. The estimated worldwide prevalence of AA is 0.1%\~0.2%, and varies with ethnicity and geographic location[@B1]. The natural history of AA also varies, depending on the disease severity. Some hairless patches can be cured with minimal treatment, but severe AA, especially alopecia totalis and alopecia universalis (AU), is difficult to manage. Conventional treatments include systemic corticosteroid and local steroid injections[@B2][@B3][@B4]. Immunomodulators such as cyclosporine and azathioprine are also used[@B5][@B6][@B7]. However, some cases of AA remain intractable or experience frequent recurrence necessitating novel treatment options.

Methotrexate (MTX) was originally developed as a chemotherapeutic agent and acts as an antimetabolite and antifolate. MTX is used to treat many autoimmune disorders, including rheumatoid arthritis, dermatomyositis, lupus, and Crohn\'s disease[@B8]. In dermatology, MTX is often used to treat psoriasis and chronic eczema[@B9]. Weekly administration of 7.5\~20 mg of methotrexate (low-dose MTX, LD-MTX) is considered generally safe and tolerable[@B10]. In this study, we evaluated the efficacy and tolerability of LD-MTX in treatment of AA multiplex who previously failed to respond to several conventional topical and/or systemic treatment.

MATERIALS AND METHODS
=====================

Subjects
--------

This retrospective study reviewed the charts of 29 patients who were diagnosed with AA and treated with LD-MTX, from January 2008 to August 2014 in the Dermatology Clinic of Chungnam National University Hospital (IRB no. CNUH 2015-12-007). We defined recalcitrant AA as no response to more than 3 types of treatments with disease duration more than 6 months. The initial weekly dosage of MTX was 10 mg and increased by 2.5 mg every two weeks. During LD-MTX treatment, folic acid was supplied to all patients and complete blood cell counts and liver and kidney function tests were done at baseline, 1 month and every 3 months thereafter during the follow-up period. The duration of follow-up period after stopping LD-MTX treatment ranged from 12 to 20 months.

Clinical assessment
-------------------

At baseline, we evaluated the severity of AA according to the Severity of Alopecia Tool (SALT)[@B11]. We also collected information on disease duration, previous treatments, MTX doses, treatment duration, relapse, disease-free duration and adverse events. The clinical response to hair regrowth was classified as follows: A0, no change or further loss; A1, 1%\~24%; A2, 25%\~49%; A3, 50%\~74%; A4, 75%\~99%; A5, 100%[@B12].

Statistical analysis
--------------------

Statistical analysis was performed using software (IBM SPSS Statistics ver. 22.0; IBM Co., Armonk, NY, USA).

RESULTS
=======

Patient demographics are summarized in [Table 1](#T1){ref-type="table"}. The median age was 40.31 (range, 16\~65) years; 16 patients were male and 13 were female. The mean disease duration was 29.03±32.61 months. The patients previously received triamcinolone local injection (100.0%), topical corticosteroid (100.0%), methylprednisolone pulse therapy (24.1%), narrow-band ultraviolet B treatment (44.8%) or systemic steroid therapy (31.0%).

The initial dose of MTX was 10 mg/week, and the mean maximum dose was 14.48 (range, 10\~17.5) mg/week. The total cumulative dose was 350.86 (range, 165\~990) mg and the mean treatment duration was 28.1 (range, 12\~74) weeks.

Twenty-six of twenty-nine patients had clinical improvement after LD-MTX treatment. There were 14 patients (48.3%) in A5 and 12 patients (41.4%) in A4 ([Fig. 1](#F1){ref-type="fig"}). However, 3 patients had poor response (A1: 3.4% \[n=1\], A2: 6.9% \[n=2\]). Regarding the severity of alopecia, most of S2 patients had clinical improvement (A5: 47.8% \[n=11\], A4: 43.5% \[n=10\]) and all 5 patients of S3 and S4 groups showed clinical improvement. However, 2 patients in S2 and 1 patient in S5 had no clinical improvement during LD-MTX treatment ([Table 2](#T2){ref-type="table"}).

Considering the disease duration, all patients who had less than 24 months disease duration showed significant clinical improvement (A5: n=9 \[31.0%\], A4: n=10 \[34.5%\]). Of the 10 patients with disease durations exceeding 24 months, 3 (30.0%) patients had no clinical improvement to LD-MTX treatment. We used the Mann-Whitney test to compare the response to therapy according to duration before treatment. The outcome was significantly different between the 6\~24 months group and 24 months or more group (*p*=0.013). The outcome did not differ significantly between 12 months or less group and 13\~24 months group (*p*=1.000).

The duration of follow-up after stopping the LD-MTX ranged from 12 to 20 months (15.26±2.80). Relapse occurred in 31.0% (n=9) of patients with \>75% regrowth and the mean disease-free duration was 11.9 months (6\~20 months).

The treatments were well tolerated by most patients but liver enzyme levels became elevated in three patients (10.3%), although no symptoms were evident. MTX therapy was stopped immediately and the patients were referred to a hepatologist. Three patients (10.3%) experienced gastrointestinal discomfort. It was transient and the symptoms disappeared after stopping the LD-MTX treatment. One patient developed lymphopenia and another showed reactivation of pulmonary tuberculosis ([Table 3](#T3){ref-type="table"}).

DISCUSSION
==========

In this study, we showed that LD-MTX is a useful treatment option for intractable AA multiplex. This result is similar to those of previous studies. Chartaux and Joly[@B13] reported complete regrowth in 57% of the patients treated with MTX alone. Droitcourt et al.[@B14] also reported a 50% complete response using combination therapy with a high-dose pulse corticosteroid and MTX, although it was less effective in children. Oral dexamethasone afforded a similar response rate (37%) in AA patients, although relapse was frequent (74%) and adverse events were more common (30%)[@B15]. There are several reports using MTX in AA with systemic corticosteroids to increase the therapeutic efficacy[@B13][@B14][@B16]. Systemic corticosteroids is effective in treating AA but side-effects during long-term therapy and relapse after dose reduction or withdrawal have restricted their use[@B17]. To avoid the side-effects caused by corticosteroids, we evaluated the efficacy and safety of LD-MTX alone in AA resistant to several conventional therapies.

Using the SALT score, most of the S1 to S4 patients had clinical improvement with LD-MTX treatment (26 of 28 patients \[92.86%\]). Despite the high efficacy of LD-MTX in this study, one S5 patient with AU had no clinical improvement. For AU patients, there is no satisfactory treatment option. Regarding the disease duration, all patients with durations less than 24 months had significant clinical improvement, while patients with disease duration exceeding 24 months showed no response to LD-MTX treatment. Similar to our results, other studies also have suggested that disease duration is an important prognostic factor in AA[@B7][@B18].

Studies reporting recurrence rate after MTX treatment in AA is highly variable. A previous study found an 80% relapse rate and another recent study reported 33% relapse rate in patients with more than 50% regrowth[@B13][@B19] In our study, 9 patients (31.0%) with \>75% hair regrowth experienced recurrent of disease. The difference between recurrence rates may be due to differences in the severity of disease, disease duration, cumulative MTX dose and concomitant medication.

No consensus has been reached on the optimal LD-MTX treatment duration, maintenance dosage or concomitant use of MTX with glucocorticosteroid. In our series, the mean treatment duration was 28.1 (range, 12\~74) weeks. One study recommended that MTX treatment be continued for 18\~24 months[@B12]. Another reported hair regrowth after 18 months of MTX treatment[@B14]. The further study will be needed to evaluate the efficacy of longer treatment duration and maintenance treatment after LD-MTX.

Though the treatments were well tolerated by most patients, some patients experienced side-effects. The most common side-effect was an abnormal liver function. The patients had no symptoms, such as fatigue, anorexia, or poor general condition. The abnormalities were detected only on regular check-ups performed during LD-MTX treatment. The changes were transient; the enzyme levels normalized after stopping MTX treatment. Previous study found that about 9% of patients on LD-MTX experienced transient elevations in transaminase levels[@B16]. When MTX is prescribed, it is essential to perform regular check-ups, including complete blood cell counts and liver function tests. Both baseline and follow-up chest x-rays are also important to check for re-activation of pulmonary tuberculosis. If problems are detected early, the adverse events may be reversible.

In conclusion, this study identified clinical benefit and safety for LD-MTX alone as a treatment option for patients with intractable and recurring AA. During treatment, regular check-ups, including complete blood cell counts and liver enzyme tests, are necessary. Further prospective studies are required to establish the optimal treatment duration, minimum effective maintenance dose to maintain the remission and timing of drug discontinuation.
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###### Demographic characteristics of the patients (n=29)
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  Characteristic                      Value
  ----------------------------------- ----------------
  Mean age (yr)                       40.31 (16\~65)
  Sex                                 
   Male                               16
   Female                             13
  Mean disease duration (mo)          29.03±32.61
  Severity of alopecia                
   S1                                 0 (0)
   S2                                 23 (79.3)
   S3                                 4 (13.8)
   S4                                 1 (3.4)
   S5                                 1 (3.4)
  Previous treatments                 
   Triamcinolone local injection      29 (100.0)
   Topical corticosteroid             29 (100.0)
   Methylprednisolone pulse therapy   7 (24.1)
   Ultraviolet B                      13 (44.8)
   Systemic steroid                   9 (31.0)
   Cryotherapy                        8 (27.6)
   Sulfasalazine                      1 (3.4)
   Diphenylcyclopropenone             2 (6.9)
   Cyclosporin                        3 (10.3)
  Previous treatment type             
   3 types of treatment               14 (48.3)
   4 types of treatment               15 (51.7)

Values are presented as mean (range), number only, mean±standard deviation, or number (%).

###### Efficacy of low-dose methotrexate treatment according to Severity of Alopecia Tool score
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              A1        A2          A3   A4          A5
  ----------- --------- ----------- ---- ----------- -----------
  S2 (n=23)   1 (4.3)   1 (4.3)     0    10 (43.5)   11 (47.8)
  S3 (n=4)    0         0           0    2 (50.0)    2 (50.0)
  S4 (n=1)    0         0           0    0           1 (100.0)
  S5 (n=1)    0         1 (100.0)   0    0           0

Values are presented as number (%). The sum of the percentages does not equal 100% because of rounding.

###### Adverse events of low-dose methotrexate treatment
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  Adverse events                 n (%)
  ------------------------------ ----------
  Abnormal liver function test   3 (10.3)
  Gastrointestinal discomfort    3 (10.3)
  Lymphopenia                    1 (3.4)
  Pulmonary tuberculosis         1 (3.4)
